News Merck charts course out of CDMO business with Lonza sale Merck KGaA has moved to streamline its focus with the sale of its contract development and manufacturing organisation (CDMO) business to Lonza.
R&D More than manufacturing: The value of a patient-centric CDMO For a biopharmaceutical company, contracting a CDMO that considers itself accountable to the patients can deliver a tangibly different experience.
R&D Bringing therapies to patients quicker with integrated CDMO ... Biotechs and pharmaceutical companies can receive enormous value from a trusted partnership with an integrated CDMO and CRO.
Sales & Marketing Sponsored Solution Spotlight: Accelerator Drug Development Thermo Fisher Scientific’s Accelerator Drug Development is a suite of integrated services combining CDMO and CRO to streamline drug development.
News Novo completes $16.5bn takeover of Catalent Novo Holdings' $16.5bn takeover of US CDMO Catalent has been completed, after months of debate over potential antitrust issues.
News Halozyme abandons its €2bn pursuit of Evotec Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations
News Beren's Niemann-Pick drug Lembaz cleared by FDA The FDA has approved Beren's Lembaz for Niemann-Pick disease type C, the first drug shown to extend survival in the ultra-rare inherited disorder.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.